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Introduction
The overall prevalence of overactive bladder (OAB)
in the USA is similar in men (16.1%) and women
(16.9%) but increases with age and may become
higher in men than in women after 75 years of age
(1,2). Benign prostatic hyperplasia and obstruction
(BPH and BPO) are conditions that may coexist in
men and potentially complicate OAB treatment, and
that are more common in older age groups (3). OAB
and BPH are known to impair health-related quality
of life (HRQoL) and to increase symptoms of
depression (2,4–6). Studies of OAB treatments have
focused primarily on patients with urinary inconti-
nence (UI), most of whom are women (2). As a
result, men have been under-represented in studies
of treatment for OAB, in which they typically consti-
tute < 15% of the population.
It is well established that orally administered
antimuscarinic drugs are effective in reducing symp-
toms and improving HRQoL in patients with OAB,
including those who are male (7–10). However,
patients with OAB often are prescribed medications
intended to treat BPH (11). Furthermore, anti-
muscarinic drugs are rarely prescribed together with
BPH medications, perhaps because of concern that
their anticholinergic effects may exacerbate obstructive
symptoms (11). Patients often discontinue therapy
with orally administered antimuscarinic medications
because of systemic anticholinergic effects, such as dry
mouth (12,13).
Guidelines from the 6th International Consultation
on New Developments in Prostate Cancer and Pros-
tate Diseases recommend antimuscarinic therapy for
some older men with lower urinary tract symptoms
(LUTS) (14). The guidelines on basic management
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SUMMARY
Aims: Overactive bladder (OAB) is common in men and may exist concomitantly
with benign prostatic hyperplasia (BPH) and obstruction. We present a subanalysis
of results from men with OAB in a 6-month, open-label study of treatment with
the oxybutynin transdermal system (OXY-TDS). Broad entry criteria were incorpo-
rated to yield a clinically representative population. Methods: All participants
received OXY-TDS 3.9 mg/day. Effectiveness was assessed by changes in scores on
validated questionnaires, which included the single-item Patient Perception of Blad-
der Condition (PPBC), the King’s Health Questionnaire (KHQ) and the Beck Depres-
sion Inventory-II (BDI-II). Results: The proportion of men (n ¼ 369; mean age ¼
69.6 years) who reported that their bladder condition caused moderate, severe or
many severe problems (PPBC ‡ 4) improved from 77.3% at baseline to
38.1–53.6% in subsequent months. Mean KHQ scores decreased signiﬁcantly
(p £ 0.0196) from baseline to study end in eight of 10 domains, indicating
improved health-related quality of life. The proportion of men with BDI-II score
> 12 (associated with a diagnosis of depression) decreased from 23.9% to 17.9%
(p ¼ 0.0055). Men with a history of ‘prostate problems’ or use of ‘BPH medica-
tion’ (32.2%) had KHQ domain changes that were similar (p ‡ 0.1016) to those
of other men. Most men (76.2%) reported no treatment-related adverse events;
two men (0.5%) experienced symptoms of mild urinary retention, but neither
required catheterisation. Conclusions: Oxybutynin transdermal system treatment
of men with OAB was effective and well tolerated, regardless of history of prostate
condition.
What’s known
• Combined treatment of men with and without
BPH is an evolving paradigm.
What’s new
• This article contributes signiﬁcant safety data,
from the largest study to date, in a community
use situation, where anticholinergics are
commonly used.
• The study provides signiﬁcant quality of life
beneﬁt data in a large population.
• The community usage design did not employ
inclusion or exclusion criteria that would restrict
the primary care physician from administrating
the medication in a ‘‘real life’’ setting.
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bladder training (14). For patients with persistent,
bothersome LUTS after basic management, suggested
approaches for specialised management of OAB and
bladder outlet obstruction (BOO) include both phar-
macological therapy and surgical treatment (14). The
direction of medical therapy depends on symptoms
and the results of speciﬁc tests. If patients have
mixed OAB and BOO, it is recommended that they
be treated with antimuscarinics and a1A-adrenergic
receptor antagonists (a-blockers) (14). When BOO is
the predominant condition, a-blockers are recom-
mended if patients have a small gland or a low
(< 1.5 ng/ml) prostate-speciﬁc antigen (PSA) level,
but both a-blockers and 5a-reductase inhibitors
(5-ARI) should be prescribed if patients have an
enlarged gland or a higher (> 1.5 ng/ml) PSA level
(14).
Several studies have suggested that antimuscarinics
and a-blockers can be used concurrently in men with
OAB and BOO or BPH. A randomised, controlled
efﬁcacy and safety study of extended-release toltero-
dine (TOL-ER) and tamsulosin treatment in men
(N ¼ 879) with LUTS, including OAB, concluded
that combination therapy was more efﬁcacious than
monotherapy and had similar tolerability (15). Lee
et al. (16) studied men (N ¼ 144) with LUTS who
presented consecutively to a single tertiary care cen-
tre. Patients were classiﬁed into two groups: one in
which patients had BOO alone (76/144; 53%), and a
second group in which patients had BOO plus OAB
(68/144; 47%) (16). OAB was deﬁned as involuntary
detrusor contractions at ‡ 10 cm H2O (16). Improve-
ment was deﬁned as at least a three-point reduction
in International Prostate Symptom Score (IPSS) (16).
In the group with BOO plus OAB, only 35% (24/68)
of men treated with doxazosin alone reported
improvement in symptoms at the end of the initial
3-month period (16). The response rate in this group
increased to 82% (56/68) 2 months after 2 mg tolte-
rodine twice daily was added to doxazosin therapy
(16).
An alternative to oral administration for anti-
muscarinic medication, if its use resulted in a lower
incidence of dry mouth and other anticholinergic
adverse effects, might be attractive to patients.
The oxybutynin transdermal system (OXY-TDS;
Oxytrol
 , Watson Laboratories, Morristown, NJ) has
been shown to be as effective as orally administered
oxybutynin immediate release (OXY-IR) and TOL-
ER in reducing symptoms of OAB (17,18), but
OXY-TDS is associated with a lower rate of dry
mouth (17,18). Inhibition of saliva production dur-
ing treatment with oxybutynin, a commonly used
antimuscarinic OAB drug, appears to be correlated
with plasma concentrations of the metabolite N-des-
ethyloxybutynin (19). Delivery of oxybutynin directly
through the skin with OXY-TDS avoids the ﬁrst-pass
hepatic metabolism that occurs with orally adminis-
tered oxybutynin (19). As a result, the incidence of
anticholinergic adverse events with OXY-TDS ther-
apy is similar to that with placebo transdermal treat-
ment (18,20,21).
The Multicenter Assessment of TRansdermal ther-
apy In overactive bladder with oXybutynin
(MATRIX) study was undertaken to examine the
effect of OXY-TDS therapy on HRQoL and safety in
a large, diverse population. Here, we present a
planned analysis of results from the cohort of men
who participated in MATRIX, along with a post hoc
analysis of men with and without pre-existing pros-
tate conditions, to examine the safety and effective-
ness of OXY-TDS treatment for patients with OAB.
Methods
Participant selection criteria
The MATRIX (study OXY0402; registered at Clinical-
Trials.gov as NCT00224146) was an open-label, pro-
spective, randomised, multicentre cohort study of
community-based adults with OAB. The study design
and main results, as well as data on sexual function,
have been published elsewhere (22,23). Inclusion cri-
teria consisted of one or more symptoms of OAB, as
described on the OXY-TDS label (urge UI, urgency
or frequency), age 18 years or older, and the ability
to complete questionnaires without assistance. Exclu-
sion criteria included any of the following current
conditions: uncontrolled narrow-angle glaucoma, uri-
nary retention or a treatable condition besides OAB
that could cause UI or urgency (urinary tract infec-
tion, bladder stone, bladder tumour, prostatitis and
prostate cancer). Participants could not have experi-
enced hypersensitivity to oxybutynin or other compo-
nents of OXY-TDS and could not have received prior
treatment with OXY-TDS; they also could not be resi-
dents in a nursing home or a long-term care facility.
No exclusion criteria were based on maximum
age, comorbid conditions besides those already
described, or use of concurrent medications except
other OAB treatments (or any investigational prod-
uct within the previous 30 days). Participants could
be enrolled despite current use of BPH medication
or a history of prostate cancer. Written, informed
consent was obtained from each individual before
enrolment. MATRIX was conducted in accordance
with the Declaration of Helsinki and Good Clinical
Practice guidelines. The study protocol and proce-
dures were approved by a central institutional review
board (Independent Review Consulting, Corte
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by site-speciﬁc institutional review boards.
Treatment
All participants received OXY-TDS at the US Food
and Drug Administration-approved dosage of
3.9 mg/day (two patches per week) for up to
6 months. Study centres were randomised 1 : 1
within each investigator specialty (Primary Medicine,
Obstetrics–Gynecology, Urology, Geriatrics or other)
to provide to participants standard instructions for
OXY-TDS or standard instructions plus a packet of
enhanced OAB educational materials. Assistance with
applying the ﬁrst patch was provided at the enrolling
centre; for subsequent applications, participants were
instructed to rotate the position of patch application
between the abdomen, hip and buttock. Participants
returned to the clinic for visits after 1, 3 and
6 months of treatment.
Participant assessment of treatment
effectiveness
Participants rated their global OAB severity with use
of the Patient Perception of Bladder Condition
(PPBC), a validated, single-item questionnaire (24).
Participants rated the difﬁculties caused by their
bladder condition on the following six-point scale:
‘no problems at all’ (one), ‘very minor problems’
(two), ‘minor problems’ (three), ‘moderate problems’
(four), ‘severe problems’ (ﬁve) and ‘many severe
problems’ (six).
Patient Perception of Bladder Condition assess-
ments were made at the baseline clinic visit and were
included during subsequent monthly scripted com-
puter-assisted telephone interviews (CATI).
Assessment of health-related quality of life
impairment
Data on impairment of HRQoL were acquired
through use of the King’s Health Questionnaire
 
(KHQ), which was administered in the clinic at base-
line, 3 months and 6 months. For participants who
withdrew from the study before 6 months, the KHQ
and other questionnaires were administered at the
time of discontinuation. The KHQ is a 27-item, vali-
dated instrument that is used to assess symptoms
and impairment of HRQoL in individuals with OAB
or other lower urinary tract conditions (25).
Although the KHQ was originally designed for use
with women, it was subsequently validated for use in
men (26). Results are converted to scores that per-
tain to 10 domains, with a score of zero correspond-
ing to the least HRQoL impairment and a score of
100 signifying the worst HRQoL impairment. The
minimal clinically important decrease (improvement)
for most domain scores is considered to be ﬁve
points; a decrease of three points is considered
important for the domains of General Health Percep-
tion and Symptom Severity (27).
Assessment of symptoms of depression
Information related to depression was obtained with
the Beck Depression Inventory-II
  (BDI-II), a vali-
dated 21-item questionnaire that was used to assess
the existence and severity of symptoms associated
with depression that occurred over the preceding
2 weeks (28). Each questionnaire item contains a list
of statements about a particular symptom of depres-
sion, arranged in order of increasing severity; these
items are consistent with the Diagnostic and Statisti-
cal Manual of Mental Health Disorders, Fourth Edi-
tion. BDI-II summary scores can range from zero
(least depression) to 63 (greatest depression); a score
> 12 is associated with a clinical diagnosis of depres-
sion.
Participant-reported satisfaction
with treatment
Participants were queried about their perceptions of
the OXY-TDS patch during the monthly, scripted
CATI sessions. Those who had been treated previ-
ously for OAB were asked to compare characteristics
of OXY-TDS with those of their prior therapy.
Assessment of safety
Safety was assessed by reports of adverse events
recorded at postbaseline clinic visits (at 1, 3 and
6 months), or as they were reported at any time dur-
ing the study. Investigators categorised adverse events
by severity (mild, moderate or severe) and by possi-
ble causal relationship (related or not related) to
treatment.
Statistical analysis
To provide sufﬁcient statistical power for analyses of
patient subgroups, the target population size was set
at approximately 2500 participants. Analyses of effec-
tiveness were performed with the intent-to-treat pop-
ulation, which comprised all participants who
received at least two doses of OXY-TDS and under-
went at least one postbaseline assessment. The pri-
mary effectiveness end-point in MATRIX was mean
change in KHQ domain scores from baseline to
study end; analyses of select KHQ item responses
also are presented here. A post hoc analysis of KHQ
results was conducted for men with and without
pre-existing prostate problems. Secondary effective-
ness end-points included self-reported changes in
global OAB condition (PPBC score), mean change
from baseline to study end in BDI-II summary score,
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Safety was analysed for all participants who received
at least one dose of OXY-TDS.
The signiﬁcance of differences between groups in
continuous variables was determined by analysis of
co-variance (ANCOVA). For comparison of baseline
differences, the ANCOVA model included controls
for investigator specialty. For end of study differ-
ences, controls included investigator specialty and
baseline value, their interaction, and patient age. A
chi-squared test was used to compare baseline differ-
ences in proportions of categorical variables. The
Cochran–Mantel–Haenszel (CMH) test was used to
compare baseline differences in proportions of
ordered categorical variables. A one-sample, two-
tailed t-test was used to assess the signiﬁcance of
mean changes in continuous variables (KHQ domain
scores and BDI-II summary score) within groups
from baseline to study end. The kappa test of sym-
metry was used to assess the signiﬁcance of changes
from baseline in PPBC scores at 3 and 6 months
among participants with postbaseline values. The
kappa test of symmetry was also used to determine
the signiﬁcance of changes in individual KHQ ques-
tionnaire response items from baseline to study end;
for display, response items were grouped as
‘improved,’ ‘stayed the same’ or ‘worsened’.
McNemar’s test was used to calculate p-values for
frequencies of paired data. CATI results were analy-
sed with descriptive statistics.
Results
Participants
A total of 2888 individuals were enrolled at 327
study centres distributed throughout the continental
USA (22). The analysis population consisted of all
participants who were treated with OXY-TDS (N ¼
2878) (22). A substantial number of men (n ¼ 369;
12.8%) participated, although most participants were
female (n ¼ 2508; 87.2%) (22). Demographic and
baseline disease characteristics of male participants
are presented in Table 1. Men in MATRIX were sig-
niﬁcantly (p < 0.0001; ANCOVA) older than female
study participants (mean, 69.6 vs. 61.4 years); 71.3%
of men (n ¼ 263) were 65 years or older. Most men
were Caucasian (n ¼ 309; 83.7%), and about one-
quarter were employed (n ¼ 87; 23.6%). OAB symp-
toms had started ‡ 4 years ago in 39.3% of men. A
majority of men (n ¼ 207; 56.4%) had been treated
at some time for OAB; the most common prior
treatments were TOL-ER (n ¼ 104; 28.2%),
extended-release oxybutynin (n ¼ 85; 23.0%), imme-
diate-release tolterodine (TOL-IR; n ¼ 46; 12.5%)
and OXY-IR (n ¼ 42; 11.4%). Cardiovascular disease
was the most common type of comorbidity (n ¼
245; 66.4%), and male participants most commonly
used concomitant medications related to treatment
of this condition: 147 (39.8%) lipid-modifying
agents, 139 (37.7%) anti-thrombotic agents and 131
(35.5%) agents that act on the renin–angiotensin sys-
tem. Nearly all men (n ¼ 320; 86.7%) were taking at
least one concomitant medication.
About one-third of men (119/369; 32.2%) had
pre-existing prostate problems; of these, 67 were con-
currently receiving BPH medication (a-blocker and/
or 5-ARI). Men with prostate problems were older
than other male participants (mean age, 73.0 vs.
68.0 years; p ¼ 0.0010; ANCOVA) but were similar
in ethnicity (p ¼ 0.4122; chi-squared test) and
employment status (p ¼ 0.4783; chi-squared test).
The proportions of men with and without prostate
problems were well balanced for diuretic use at base-
line (26.1% vs. 20.4%; p ¼ 0.2223; chi-squared test).
Time since onset of OAB symptoms was similar
(p ¼ 0.3310; CMH test) in the two groups. A higher
Table 1 Demographic and baseline characteristics of
male participants
Characteristics Men (n ¼ 369)
Age, years
Mean (standard deviation) 69.6 (13.1)
Median (range) 72.0 (20–96)
Race, n (%)
White 309 (83.7)
Black 36 (9.8)
Asian 10 (2.7)
Hispanic 9 (2.4)
Others 5 (1.4)
Employment status*, n (%)
Employed 87 (23.6)
Not employed 281 (76.4)
Comorbid conditions by body system, n (%)
Cardiovascular 245 (66.4)
Musculoskeletal 169 (45.8)
Gastrointestinal 138 (37.4)
Endocrine 116 (31.4)
Neurological/psychiatric 113 (30.6)
Renal 82 (22.2)
Respiratory 74 (20.1)
Dermatological 50 (13.6)
Haematological/lymphatic 24 (6.5)
Others 204 (55.3)
Number of concurrent medications
Mean (standard deviation) 5.8 (4.7)
Median (range) 5 (0–21)
*One participant did not respond. Working part time or full
time, with or without pay. Unemployed, disabled, retired or
other.
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118 respondents; 61.9%) than without (134 of 249
respondents; 53.8%) had been treated previously for
OAB; men with prostate problems (29/119; 24.4%)
were more likely than other men (46/250; 18.4%) to
have taken multiple OAB medications previously.
More men with prostate problems than men without
prostate problems had discontinued prior OAB treat-
ments because of ineffectiveness (61.2% vs. 56.3%
respectively) and fewer because of compliance (2.6%
vs. 8.9%), but other reasons for discontinuation of
prior OAB therapies were given with similar fre-
quency (‘side effects’, 21.6% vs. 19.8%; other, 12.9%
vs. 12.5%; unknown, 1.7% vs. 2.6%).
Participant-reported perceptions of bladder
condition
At the baseline clinic visit, most male participants
who responded to the PPBC (255/330; 77.3%)
reported a global OAB severity score of ‡ 4
(Figure 1A). This percentage decreased sharply after
1 month of OXY-TDS treatment and continued on
a declining trend for the remainder of the study
(Figure 1A). At baseline, 16.5% of male respondents
A
B
Figure 1 Participant-reported measures of bladder condition; percentages are calculated on the basis of the total number of
respondents at each evaluation. (A) Percentage of respondents who rated their global overactive bladder (OAB) severity as 1,
2 or 3 (no problems at all, very minor problems or some very minor problems) or 4, 5 or 6 (moderate problems, severe
problems or many severe problems) with the Patient Perception of Bladder Condition (PPBC) questionnaire. (B) Percentage
of respondents who reported feeling that they had enough time to get to the bathroom during the past month
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get to the bathroom (Figure 1B). After 1 month,
the proportion who ‘always’ had enough time to
get the bathroom had approximately doubled
to 33.9% (75/221); the proportion was stable or
increased slightly over the next 5 months
(Figure 1B).
KHQ response items and health-related quality
of life
At baseline, men in the study showed impairment of
HRQoL in all 10 domains of the KHQ (Figure 2).
The most impaired domains (highest scores) were
Incontinence Impact, Symptom Severity, Sleep/
Energy and Physical Limitations (Figure 2). By study
end, scores had improved in all KHQ domains, and
changes were statistically signiﬁcant (p £ 0.0196;
t-test) in eight of 10 domains (Figure 2). Changes
were clinically meaningful in four of these eight
domains: Incontinence Impact, Symptom Severity,
Sleep/Energy and Role Limitations. The greatest
absolute improvement was noted in the Incontinence
Impact domain (mean change of )8.9 points), and
the greatest relative improvement was seen in the
Role Limitations domain (mean change of )21.0%).
For 16 KHQ items, measured at baseline and
study end, signiﬁcantly more male participants
reported improvement of symptoms than the num-
ber who reported worsening of symptoms (Figure 3).
This was most evident in response items from the
domains of Incontinence Impact, Symptom Severity,
Role Limitations, Sleep/Energy and Severity (Coping)
Measures (Figure 3). For the remaining KHQ items,
no signiﬁcant difference was noted in the number of
participants who reported improvement or worsen-
ing of symptoms.
Health-related quality of life in men with
and without pre-existing prostate problems
Men with and without pre-existing prostate problems
had similar (p ‡ 0.1575; ANCOVA) baseline scores
in all 10 KHQ domains. HRQoL improved in both
groups from baseline to study end, as was shown by
mean decreases in nine of 10 KHQ domain scores
31.3
63.8
50.2
36.6
38.6
26.4
19.1
28.1
46.8
34.2
23.9
16.7
33.5 ‡
23.1 †
37.9 *
29.9 *
28.7 *
42.7 *
54.8 *
29.4 § 
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General health perception
Incontinence impact
Symptom severity
Role limitations
Physical limitations
Social limitations
Personal relationships
Emotions
Sleep/energy
Severity (coping) measures
Mean KHQ domain score
Baseline
Study end
KHQ domain
Figure 2 Health-related quality of life (HRQoL) of male participants at baseline and at study end, assessed as mean King’s
Health Questionnaire (KHQ) domain scores. *p < 0.0001, p < 0.001, p < 0.01, §p £ 0.0196; one-sample t-test for
signiﬁcance of difference from zero for change in baseline value; other changes were not statistically signiﬁcant
(p ‡ 0.1033)
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ANCOVA) in all 10 domains for both groups.
Symptoms of depression
The mean BDI-II summary score at baseline for men
in the study was 8.5 points; the median score was
7.0. By study end, the mean BDI-II summary score
had improved signiﬁcantly (p < 0.0001; t-test) to
7.1 – a decrease of 16.5%. Median BDI-II summary
score decreased to 6.0 by study end. Among partici-
pants with postbaseline data, the proportion of men
with a BDI-II summary score > 12, which is associ-
ated with a diagnosis of clinical depression, decreased
signiﬁcantly, from 23.9% (72/301) at baseline
to 17.9% (54/301) at study end (p ¼ 0.0055;
McNemar’s test).
Participant-reported satisfaction with
treatment
Most male participants (61.6–71.3%) were ‘very satis-
ﬁed’ or ‘satisﬁed’ with OXY-TDS throughout the
study (Figure 5A). Conversely, a low proportion (8.6–
15.4%) were ‘dissatisﬁed’ or ‘very dissatisﬁed’ (Fig-
ure 5A). Similar results were obtained for questions
about convenience, effectiveness and tolerability of the
patch (data not shown). Most male participants who
15.8
11.9
10.9
20.1
20.1
15.5
11.7
18.7
14.3
13.0
11.8
18.3
18.2
13.1
14.8
12.2
28.0 §
30.9 §
22.6 §
27.1 ‡
28.1 ‡
31.0 ‡
32.3 ‡
37.6 ‡
30.6 †
35.9 *
33.6 *
31.6 †
40.6 †
37.7 *
36.0 *
35.9 *
0 1 02 03 04 05 0
Incontinence impact
Frequency
Nocturia
Urgency
Urge incontinence
Household tasks
Job/daily outside activities
Physical activities
Feel anxious/nervous
Feel bad about yourself
Effect on sleep
Feel worn out/tired
Be careful of how much you drink
Change underclothes when they get wet
Worry that you smell
Embarrassed because of bladder problem
Percentage of participants
Worsened
Improved
KHQ response item
Symptom 
severity
Role 
limitations
Sleep/energy
Incontinence 
impact
KHQ domain
Severity 
(coping) 
measures
Emotions
Physical 
limitations
Figure 3 Percentage of male participants who reported improvement or worsening, from baseline to study end, in
symptoms described in individual King’s Health Questionnaire (KHQ) response items. Participants who reported that
their symptoms ‘stayed the same’ are not depicted. Only responses for which statistically signiﬁcant differences were
noted are displayed. *p < 0.0001, p < 0.001, p < 0.01, §p £ 0.0488; kappa test of symmetry; other comparisons were
not signiﬁcantly different (p ‡ 0.1781)
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said that the patch offered signiﬁcant or some beneﬁts
over previous treatments, suggesting that they pre-
ferred the patch over their prior therapy (Figure 5B).
A small proportion preferred their previous medica-
tions (7.2–12.8%). Similar opinions of the patch vs.
prior therapy were reported with respect to ease of
use, effectiveness and tolerability (data not shown).
Safety
Oxybutynin transdermal system was well tolerated;
most men in the study (281/369; 76.2%) experienced
no drug-related adverse event during up to 6 months
of treatment. The most common type of treatment-
related adverse event, application site reaction,
occurred in 13.8% (51/369) of male participants
(Table 2). The vast majority of these reactions (71/73;
97.3%) were judged mild or moderate in severity.
Treatment-related anticholinergic adverse events were
infrequently reported by male participants: dry mouth
(n ¼ 9; 2.4%), nausea (n ¼ 5; 1.4%), headache (n ¼
4; 1.1%), constipation (n ¼ 4; 1.1%), dizziness (n ¼
3; 0.8%), abdominal pain (n ¼ 2; 0.5%), dry eye
(n ¼ 1; 0.3%) and dysuria (n ¼ 1; 0.3%). The male
participant who experienced treatment-related mild
dysuria continued study treatment after a 2-day hia-
tus. A total of 47 men (12.7%) discontinued study
participation because of a treatment-related adverse
event. No male participants experienced a serious
treatment-related adverse event.
Two participants (2/369; 0.5%) from the male
cohort each reported one event of urinary retention,
both of which were considered related to treatment.
However, these events were mild in severity and nei-
ther required catheterisation. One participant who
experienced urinary retention continued treatment
with OXY-TDS, and the other discontinued treat-
ment. Male and female study participants had com-
parable rates of urinary retention [2/369 men (0.5%)
vs. 8/2508 women (0.3%)] and dysuria [1/369 men
(0.3%) vs. 14/2508 women (0.6%)].
Discussion
This planned subgroup analysis of MATRIX partici-
pants was among the longest-term, single, prospec-
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Figure 4 Improvement in health-related quality of life (HRQoL) in men with and without pre-existing prostate problems,
assessed as mean changes in King’s Health Questionnaire (KHQ) domain scores from baseline to study end. All changes
in score were similar between the two groups (p ‡ 0.1016); analysis of co-variance (ANCOVA)
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treatment for OAB in a large cohort of men. As
intended, the study population was representative of
actual patients with OAB in terms of advanced age,
comorbidity and use of concomitant medications.
Many study participants had not persisted with pre-
vious OAB treatments, which also is a common char-
acteristic of patients with OAB in the general
population (12). MATRIX was the ﬁrst study of men
with OAB to have a patient-reported outcome (i.e.
change in HRQoL) as its primary end-point. Con-
current use of the PPBC allowed comparison of par-
ticipant-reported changes in global OAB severity,
independent of the symptoms and HRQoL changes
measured with the KHQ. This study did not have a
placebo or active control; therefore, results cannot
determine causal relationships. However, the open-
label design was closer to clinical practice than
blinded treatment. The large population size, mini-
mally restrictive entry criteria and 6-month duration
of the study also allowed better estimation of the
incidence of relatively rare adverse events.
Global OAB severity in male participants, as self-
assessed with the PPBC, improved distinctly from
baseline to month 1 and continued to improve
slightly during the remaining 5 months. Perceived
urinary urgency (not enough ‘time to get to the
bathroom’), which is a deﬁning symptom of OAB,
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global OAB severity. This perceived change in uri-
nary urgency is consistent with the signiﬁcant
(p < 0.001; kappa test of symmetry) improvement
noted in the KHQ ‘urgency’ response item. Other
symptoms and HRQoL items recorded with the
KHQ also improved signiﬁcantly during the study.
These results are similar to those from a pooled anal-
ysis of two studies in men with OAB, in which treat-
ment with TOL-ER signiﬁcantly improved daytime
and 24-h micturitions, although not nighttime
micturitions (29). In MATRIX, treatment with
OXY-TDS was associated with signiﬁcant
(p < 0.0001; kappa test of symmetry) improvement
in urinary frequency and nocturia, as assessed
through KHQ response items. The degree of HRQoL
improvement in MATRIX was unaffected by pre-
existing prostate conditions or the concomitant use
of medications to treat BPH. These results are con-
sistent with those of a randomised, controlled study
of men with OAB and other LUTS, in which signiﬁ-
cantly more patients (172/215; 80%; p < 0.001) treat-
ed with TOL-ER and an a-blocker (tamsulosin)
reported treatment beneﬁt, compared with patients
who received placebo (132/214; 62%) (15).
Depression symptoms monitored with the BDI-II
decreased signiﬁcantly during the study for men
treated with OXY-TDS. The KHQ response item that
asked participants whether they ‘Feel bad about
yourself’ also showed signiﬁcant (p < 0.05; kappa test
of symmetry) improvement from baseline to study
end. No other studies have shown improvement in
depression among men being treated for OAB.
Indeed, little evidence to date suggests that treatment
improves depression symptoms in any population of
patients with OAB, despite evidence that depression
symptoms are common in these individuals (4).
Kelleher et al. found no signiﬁcant effect of TOL-ER
or TOL-IR vs. placebo on the SF-36 Mental Sum-
mary score (7,30).
The number of male participants who were
‘satisﬁed’ or ‘very satisﬁed’ with OXY-TDS overall
was four to eightfold greater, at various times during
the study, than the number who reported being
‘dissatisﬁed’ or ‘very dissatisﬁed.’ For men with OAB
who had been previously treated, the ratio of
‘satisﬁed/very satisﬁed’ to ‘dissatisﬁed/very dissatis-
ﬁed’ also ranged from four- to eightfold at different
times during the study. Taken together, these results
suggest that perceived effectiveness, as well as
convenience and perceived tolerability, was associated
with treatment satisfaction in male participants.
Oxybutynin transdermal system was well tolerated
by the male cohort in MATRIX and no serious
adverse events were considered related to treatment.
The rate of application site reactions in men
(13.8%) was similar to that observed in the overall
MATRIX population (14.0%) and in previous stud-
ies (17,18,20,22). A low incidence of anticholinergic
adverse events was observed, despite the use of con-
comitant medications by the great majority of men.
Despite some suggestion from another study that
tolterodine and tamsulosin may have a synergistic
effect on the incidence of dry mouth, in MATRIX,
dry mouth did not occur signiﬁcantly more fre-
quently among men who took a-blockers than
among those who did not (3/56 vs. 6/307; p ¼
0.142; Fisher’s exact test) (15). No cases of acute
urinary retention requiring catheterisation were
reported in the male cohort described here, which
was followed for up to 6 months. This low proba-
bility of urinary retention observed in individuals
with BPH or other prostate problems is consistent
with results from studies of TOL-ER treatment in
patients with OAB, some of whom also had BOO
or additional LUTS (15,29,31).
The International Continence Society deﬁnition
of OAB is based on symptoms of urinary urgency,
frequency and incontinence (32). Validated ques-
tionnaires that assess changes in these symptoms
are important measures for improvement in OAB
severity (33). The European Agency for the Evalua-
tion of Medicinal Products has stated that ‘the pri-
mary aim for developing new drugs for UI should
be to obtain a subjective improvement or cure of
symptoms for the patient’ (34). In male study par-
ticipants, perceived OAB severity, OAB symptoms
and HRQoL all improved with OXY-TDS treatment.
Table 2 Treatment-related adverse events occurring in
‡ 1% of male participants
Adverse event
Male participants,
n (%)
Application site reaction* 51 (13.8)
Dry mouth 9 (2.4)
Pruritus 8 (2.2)
Erythema 5 (1.4)
Nausea 5 (1.4)
Constipation 4 (1.1)
Headache 4 (1.1)
Rash 4 (1.1)
Somnolence 4 (1.1)
*A participant may have reported more than one type of
application site (AS) reaction. Types included AS pruritus
(22; 6.0%), AS dermatitis (20; 5.4%), AS erythema (15; 4.1%),
AS irritation (6; 1.6%), AS pain (2; 0.5%), AS vesicles (2;
0.5%), AS bleeding (1; 0.3%), AS burning (1; 0.3%) and AS
swelling (1; 0.3%).
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not observed during the study; urinary retention
was rare (0.5% of all male participants) and
resolved without the need for catheterisation. Satis-
faction with treatment was good, even among
those who had discontinued prior therapies. Partic-
ipants in the present analysis were typical of OAB
patients encountered in general practice in terms
of their advanced age, multiple comorbid condi-
tions and use of many concomitant medications.
The use of questionnaires in general medical prac-
tice could allow effective treatment of many
patients without the need for specialised urody-
namic evaluations.
Although the design of MATRIX was appropriate
for its goal of evaluating therapeutic success in a
large, clinically relevant population, some inherent
limitations should be noted. The study did not
include objective assessments of response, such as
urodynamic measurements or micturition fre-
quency, but instead relied on participant-reported
outcomes. It is not known how well symptoms
recorded with the KHQ relate to symptoms mea-
sured with instruments that are commonly used to
evaluate LUTS in men, such as the IPSS or the
American Urological Association Symptom Score.
However, evidence suggests a correlation between
KHQ and IPSS results in Japanese patients (35,36).
The post hoc analysis by history of prostate prob-
lems or concomitant BPH medication use was ret-
rospective; therefore, selection bias may have
inﬂuenced the results. Nonetheless, the positive
outcomes reported in men who had a history of
prostate problems or who were using BPH medica-
tions suggest that this last study limitation was of
little consequence. In fact, a primary aim of
MATRIX was to include individuals, such as these,
who might be commonly encountered in clinical
practice, but who have been excluded from nearly
all randomised, controlled clinical trials conducted
previously.
In summary, men with OAB reported improved
OAB severity, HRQoL and depression symptoms
after treatment with OXY-TDS. Treatment effects
were similar in men with or without pre-existing
prostate problems. Participant-reported perceptions
of OXY-TDS supported the more objective measures
of effectiveness and showed a high degree of satisfac-
tion with treatment. OXY-TDS was well tolerated in
men, none of whom experienced acute urinary reten-
tion or a treatment-related serious adverse event dur-
ing up to 6 months of treatment. OXY-TDS appears
to be a viable treatment for men with LUTS, many
of whom have OAB alone or together with BPH/
BPO (37).
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